2
Announcements
Trials
Browse
Landscape
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Observational
1
Sponsor
Cancer Type
Thoracic
1
Sarcoma
1
Plasma cell
1
Other solid neoplasm
1
Other hematologic neoplasm
1
NET
1
Myeloid
1
Lymphoid
1
Head & Neck
1
Gynecologic
1
Genitourinary
1
Gastrointestinal
1
Endocrine
1
Dermatologic
1
CNS
1
Breast
1
Conditions
Lymphoma, Non-Hodgkin
4
Leukemia, Myeloid, Acute
4
Leukemia
4
Colonic Neoplasms
4
Congenital Abnormalities
3
Carcinoma, Non-Small-Cell Lung
3
Breast Neoplasms
3
Waldenstrom Macroglobulinemia
2
Somatostatinoma
2
Recurrence
2
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Neoplasms
2
Myeloproliferative Disorders
2
Multiple Myeloma
2
Melanoma
2
Lymphoma, Mantle-Cell
2
Lymphoma, Large B-Cell, Diffuse
2
Lymphoma, Follicular
2
Lymphoma
2
Lung Neoplasms
2
Leukemia, Myelomonocytic, Acute
2
Leukemia, Monocytic, Acute
2
Leukemia, Megakaryoblastic, Acute
2
Leukemia, Erythroblastic, Acute
2
Colorectal Neoplasms
2
Carcinoma, Islet Cell
2
Vulvar Neoplasms
1
Vipoma
1
Vaginal Neoplasms
1
Interventions
Everolimus
10
Octreotide
7
pasireotide
5
lanreotide
5
gallium Ga 68 dotatate
5
lutetium Lu 177 dotatate
3
cabozantinib
3
Sunitinib
3
Nivolumab
3
ganitumab
2
fluorodopa F 18
2
Temozolomide
2
Ga(III)-DOTATOC
2
Erlotinib Hydrochloride
2
Capecitabine
2
Bevacizumab
2
zimberelimab
1
veliparib
1
telotristat ethyl
1
surufatinib
1
recombinant interferon alpha 2b-like protein
1
pertuzumab
1
pembrolizumab
1
olaparib
1
nintedanib
1
ibrutinib
1
fosbretabulin
1
epothilone B
1
conatumumab
1
cixutumumab
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Carcinoid Tumor
×
Biological Therapy
×
Clear all
NCT04028479
2024-12-18
ROOT
Taproot Health
Completed
167 enrolled